Rare diseases, orphan drugs and their regulation: questions and misconceptions
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Sustained advocacy efforts driven by patients' organizations to make rare diseases a health priority have led to regulatory and economic incentives for industry to develop drugs for these diseases, known as orphan drugs. These incentives, enacted in regulations first introduced in the United States in 1983 and later in Japan, Europe and elsewhere, have resulted in substantial improvements in the treatment for patients with a range of rare diseases. However, the advent of orphan drug development has also triggered several questions, from the definition of rarity to the pricing of orphan drugs and their impact on health-care systems. This article provides an industry perspective on some of the common questions and misconceptions related to orphan drug development and its regulation, with the aim of facilitating future progress in the field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Standard randomized placebo-controlled clinical trials in hundreds of patients will therefore be difficult to achieve for ASD, and specific clinical trials designed for rare diseases need to be devised 90 .”
From Progress toward treatments for synaptic defects in autism (2013) · cites this paper as [90]
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“, although others claim that this number could be as high as 50”
BackgroundRelative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
Eichler, H.-G., Bloechl-Daum, B., Abadie, E., Barnett, D., König, F., & Pearson, S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3079 · Cited by 174
The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
Wellman-Labadie, O., & Zhou, Y. (2010) · Health Policy · doi:10.1016/j.healthpol.2009.12.001 · Cited by 166
Adopting Orphan Drugs — Two Dozen Years of Treating Rare Diseases
Haffner, M. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp058317 · Cited by 162
Orphan drug development is not taking off
Joppi, R., Bertelè, V., & Garattini, S. K. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03369.x · Cited by 64
Orphan drug policies: implications for the United States, Canada, and developing countries.
Cheung, R. Y., Cohen, J. C., & Illingworth, P. (2004) · PubMed · Cited by 49
From research on rare diseases to new orphan drug development
Heemstra, H. (2010) · Utrecht University Repository (Utrecht University) · Cited by 3
Research works printed but not linked: 5
- La Revue Prescire – Enquête. Médicaments pour les maladies rares: bilan contrasté en Europe — Synthèse élaborée collectivement par la Rédaction. La Revue Prescire 26, 781 (2006) (in French).
- Hirschhorn, R. & Reuser A. J. J. in The Metabolic & Molecular Bases of Inherited Diseases 8th edn (eds Scriver C. R. et al.) 3395 (McGraw-Hill, New York, 2001).
- Genzyme Corporation. Genzyme annual report 2004. (Genzyme, Cambridge, Massachusetts, 2004).
- The European Platform for Patients' Organisations, Science and Industry. The 8th workshop on partnering for rare disease therapy development: the reality of orphan medicines. The Platform for Patients' Organisations, Science and Industry website [ online ], (2007).
- Commission of the European Communities. Guideline on aspects of the application of Article 8(2) of Regulation (EC) No 141/2000: review of the period of market exclusivity of orphan medicinal products. The European Commission website [ online ], (2008).
Cited by
Items 101–183 of 183
Evaluation of galsulfase for the treatment of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)
Lourenço, C. M., & Giugliani, R. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.885833 · Cited by 6
Marketing authorisation of new medicines in the EU: towards evidence-based improvement
Putzeist, M. (2013) · Utrecht University Repository (Utrecht University) · Cited by 9
Clinical trial evidence supporting FDA approval of novel orphan drugs between 2017 and 2023
Chen, Q., Xu, Y., Qu, R., Luo, X., & Yue, Y. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104102 · Cited by 5
The Challenges of Clinical Research in Orphan Diseases
Spagnolo, P., & du Bois, R. M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-2401-6_2 · Cited by 5
Rare diseases and space health: optimizing synergies from scientific questions to care
Puscas, M., Martineau, G., Bhella, G., Bonnen, P. E., Carr, P., Lim, R. R., Mitchell, J. J., Osmond, M., Urquieta, E., Flamenbaum, J., et al. (2022) · npj Microgravity · doi:10.1038/s41526-022-00224-5 · Cited by 6
Wang, X., Li, S., Yue, X., Li, Y., Shi, N., Zhao, F.-L., & Wu, J. (2022) · Value in Health Regional Issues · doi:10.1016/j.vhri.2022.10.008 · Cited by 5
Gicquel, T., Cortial, L., Lutsyk, K., Forget, S., Braun, S., Boyer, P.-O., Laugel, V., & Blin, O. J. (2023) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2023.29 · Cited by 5
The Role of Brain Tumor Advocacy Groups
Rhee, M., Mui, P., Cadogan, C., Imerman, J., Lindsell, S., & Samant, L. T. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0442-z · Cited by 5
Picavet, E., Cassiman, D. M., Aertgeerts, B., & Simoens, S. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-157 · Cited by 5
EVALUATION OF PHARMACISTS’ KNOWLEDGE AND ATTITUDES REGARDING RARE DISEASES AND ORPHAN DRUGS
Krajnović, D., Arsić, J., Jocić, D., Georgiev, A. M., Tasić, L., & Marinkovic, V. D. (2013) · Acta Medica Medianae · doi:10.5633/amm.2013.0204 · Cited by 5
Li, Y., Du, P., Zhang, X., Ren, C., Shi, X., Dong, X., & Zhang, C. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02987-w · Cited by 4
Rodríguez, M. C., Ceaglio, N., Antuña, S., Tardivo, M. B., Etcheverrigaray, M., & Prieto, C. C. (2017) · Biotechnology Progress · doi:10.1002/btpr.2538 · Cited by 4
Charco, J. M., Barrio, T., & Eraña, H. (2021) · Araucaria · doi:10.12795/araucaria.2021.i46.21 · Cited by 6
Examining of Health Policy in Rare Diseases in Terms of Historical Perspective in Turkey
Güre, M. D. P., & İNCE, Ö. (2021) · Journal of International Health Sciences and Management · doi:10.48121/jihsam.874683 · Cited by 5
Haqyar, A., Raissi, ., Farzad, F., & Hashemzadeh, H. (2022) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2022.109281 · Cited by 3
Políticas da 'expertise': doenças raras e gestão das tecnologias em saúde pelo SUS
Oliveira, C. R. C., Melamed, C., & Machado, R. R. (2011) · Americanae (AECID Library) · Cited by 3
Gaucher Disease: A Glance from a Medicinal Chemistry Perspective
Prencipe, F., Barzan, C., Savian, C., Spalluto, G., Carosati, E., Amici, M. D., Mosconi, G., Gianferrara, T., Federico, S., & Ros, T. D. (2024) · ChemMedChem · doi:10.1002/cmdc.202300641 · Cited by 5
Douglas, C. M. W., Panagiotoglou, D., Dragojlovic, N., & Lynd, L. D. (2021) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2021.120960 · Cited by 7
Drug discovery in rare indications: opportunities and challenges
Richon, V. M. (2013) · Hematology · doi:10.1182/asheducation-2013.1.19 · Cited by 3
Wessler, S. (1987) · PubMed · Cited by 3
Application of In Silico Drug Repurposing in Infectious Diseases
Kumar, P., & Ghosh, I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816125-8.00015-8 · Cited by 2
Pharmaceutical policy and innovation for rare diseases: A narrative review
Ruiz, A. A., Large, K. E., Moon, S., & Vieira, M. (2023) · F1000Research · doi:10.12688/f1000research.130809.1 · Cited by 12
García-Parra, B., Guiu, J. M., Povedano, M., & Modamio, P. (2024) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2024.2400522 · Cited by 2
Thatte, U. M., Gogtay, N. J., Sridharan, K., & Oak, S. (2012) · PubMed · Cited by 2
Mizoguchi, H., & Kano, S. (2019) · Scientometrics · doi:10.1007/s11192-019-03129-5 · Cited by 2
The Research Landscape of Multiple Endocrine Neoplasia Type 1 (2000–2021): A Bibliometric Analysis
Feng, C., Chen, H., Huang, L., Feng, Y., & Chang, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.832662 · Cited by 2
The inborn errors of metabolism: General aspects
Cox, T. M., & Watts, R. W. E. (2020) · doi:10.1093/med/9780198746690.003.0225 · Cited by 2
Фотеева, А. В., Koneva, N. A., Beloglazova, O. S., & Rostova, N. B. (2023) · Drug development & registration · doi:10.33380/2305-2066-2023-12-2-198-205 · Cited by 1
Anderson, G. P., Flynn, A. W. P., Bardin, P. G., Blakey, J., Dharmage, S. C., Foster, P. S., Gibson, P. G., Jaffé, A., James, A., Jenkins, C. R., et al. (2025) · The Medical Journal of Australia · doi:10.5694/mja2.70094 · Cited by 1
Application of nanotechnology in lysosomal storage diseases
Hossain, E., Sarkhel, S., Mandal, S., & Biswas, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-28942-2.00005-3 · Cited by 1
Douglas, C. M. W., Kleinhout‐Vliek, T., Hagendijk, R., Rabeharisoa, V., Boon, W., Aith, F., Cláudio Cordovil Oliveira, U. F. R. J., Grunebaum, S., & Moors, E. H. M. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-04132-1 · Cited by 1
Qualitative needs assessment of financial impact on caregivers of children living with rare diseases
Delval, F., & Levine, J. A. (2026) · Rare · doi:10.1016/j.rare.2026.100119 · Cited by 1
Emerging Technologies for Gene Identification in Rare Diseases
Beleggia, F., & Wollnik, B. (2014) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-017-9214-1_3 · Cited by 1
Tang, Q., Song, P., & Chen, Y. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1180244 · Cited by 1
Allamneni, K. P., Parker, S., O’neill, C. A., Wright, T. L., King, S. T., & Andrews, L. (2016) · International Journal of Toxicology · doi:10.1177/1091581816644709 · Cited by 1
The importance of the policy framework on orphan drug accessibility
Jakob, U., & Daumann, F. (2023) · Journal of Public Health · doi:10.1007/s10389-023-01899-0 · Cited by 1
Rare diseases: What rheumatologists need to know?
do Nascimento, R. R. N. R., Piotto, D. G. P., Freire, E. A. M., Neves, F. D. S., Sztajnbok, F., Bica, B. E. R. G., Pinheiro, F. A. G., Kozu, K. T., Pereira, I. A., Azevedo, V. F., et al. (2024) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-024-00407-6 · Cited by 2
Market access procedures for orphan drugs
Wilson, C. (2013) · Elsevier eBooks · doi:10.1533/9781908818393.247 · Cited by 1
Treating Rare Diseases: Business Model for Orphan Drug Development
Williams, C. S. M. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00083 · Cited by 1
Degrassat-Théas, A., Paubel, P., Sinègre, M., de Curzon, O. P., & Pen, C. L. (2016) · Journal de gestion et d économie médicales · doi:10.3917/jgem.154.0221 · Cited by 1
Seltene Erkrankungen in der Pneumologie und damit verbundene Herausforderungen
Wencker, M., Teschler, H., Vogelmeier, C. F., & Koczulla, A. R. (2012) · Pneumologie · doi:10.1055/s-0032-1309876 · Cited by 1
Multi-criteria Decision Analysis for Assessing Orphan Drugs
Schey, C. (2022) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.206096858 · Cited by 1
REGULATION OF HUMAN PHARMACEUTICAL SAFETY
Gad, S. C. (2016) · doi:10.1002/9781119097440.ch2 · Cited by 1
Managing University-Industry Collaborative Innovation in the Pharmaceutical Industry
Ma, Z. (2024) · doi:10.5463/thesis.499 · Cited by 2
Consideration for Rare Diseases in the Context of Drug Reimbursement Processes
Gosain, S. (2015) · uO Research (University of Ottawa) · doi:10.20381/ruor-4352
Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives
John, J. E. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.004
Cottin, V., & Cordier, J.-F. (2014) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2014.10.725
Crilly, M. (2016) · D-Scholarship@Pitt (University of Pittsburgh)
Availability of Orphan drugs: Basic legal issues of development and financing
Stojković-Zlatanović, S. (2019) · Pravni zapisi · doi:10.5937/pravzap0-20657
Integrated Life Cycle Management for Rare and Orphan Products
Kolochavina, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-78605-2_23
Fontanet, J. M., & Torrent-Farnell, J. (2018) · Arbor · doi:10.3989/arbor.2018.789n3008
Shiomura, J., Suzuki, R., & Ozeki, M. (2011) · Drug Delivery System · doi:10.2745/dds.26.118
Schwabe, U. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_3
The Effect of Financial Pressure on Innovation in EU Strategies on Orphan Drugs
Fukuda, Y. (2014) · EU Studies in Japan · doi:10.5135/eusj.2014.270
REGULATION OF HUMAN PHARMACEUTICAL SAFETY: ROUTES TO HUMAN USE AND MARKET
Gad, S. C., & Sullivan, D. W. (2022) · doi:10.1002/9781119755883.ch2
Challenges of Clinical Research in Orphan Diseases
Spagnolo, P., & Bernardinello, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_2
Alewaidat, H., Bataineh, Z., Bani-Ahmad, M., Alali, M., & Almakhadmeh, A. (2023) · F1000Research · doi:10.12688/f1000research.130388.1
Ethical, economic and clinical aspects of financing treatment of rare diseases
Sujkowska, G. (2020) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2019.2.5
Alewaidat, H., Bataineh, Z., Bani-Ahmad, M., Alali, M., & Almakhadmeh, A. (2023) · F1000Research · doi:10.12688/f1000research.130388.2
Recent Advances in Regulatory Science for Pharmaceutical Development and Approval
(2023) · Journal of Pharmaceutical Research · doi:10.33140/jpr.08.02.05
Clinical Trial Evidence Supporting Fda Approval of Orphan Products between 2017 to 2023Preprint
Chen, Q., Xu, Y., Qu, R., Guo, Q., Luo, X., Yue, Y., & Zhou, J. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4781319
Insights into Support Systems for Orphan Drug Development: A Comparative Study
Leng, Y., Tang, Y., Yu, W., Hou, Y., He, H., Han, Y., Huang, H., Zhang, W., & Li, N. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00833-8
Orphan drugs: The final frontier in the fight against rare diseases
Rajaram, S., & Medhi, B. (2025) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_979_25
Additional file 2 of A systematic review of moral reasons on orphan drug reimbursement
Zimmermann, B. M., Eichinger, J., & Baumgartner, M. R. (2021) · Figshare · doi:10.6084/m9.figshare.14889177
Li, Y., Du, P., Zhang, X., Ren, C., Shi, X., Dong, X., & Zhang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26647872
Li, Y., Du, P., Zhang, X., Ren, C., Shi, X., Dong, X., & Zhang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26647869
Additional file 3 of A systematic review of moral reasons on orphan drug reimbursement
Zimmermann, B. M., Eichinger, J., & Baumgartner, M. R. (2021) · Figshare · doi:10.6084/m9.figshare.14889180
Li, Y., Du, P., Zhang, X., Ren, C., Shi, X., Dong, X., & Zhang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26647866
Li, Y., Du, P., Zhang, X., Ren, C., Shi, X., Dong, X., & Zhang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26647863
Li, Y., Du, P., Zhang, X., Ren, C., Shi, X., Dong, X., & Zhang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26647878
Additional file 5 of A systematic review of moral reasons on orphan drug reimbursement
Zimmermann, B. M., Eichinger, J., & Baumgartner, M. R. (2021) · Figshare · doi:10.6084/m9.figshare.14889186
Additional file 1 of A systematic review of moral reasons on orphan drug reimbursement
Zimmermann, B. M., Eichinger, J., & Baumgartner, M. R. (2021) · Figshare · doi:10.6084/m9.figshare.14889174
Li, Y., Du, P., Zhang, X., Ren, C., Shi, X., Dong, X., & Zhang, C. (2024) · Figshare · doi:10.6084/m9.figshare.26647875
Ma, X.-D., Xu, Z., & Huang, X.-J. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02839-8
Valtere, L. (2026) · Munich studies on innovation and competition · doi:10.1007/978-3-032-04060-2_5
Antoni, G. D., Kumps, C., Berger, J., Barman‐Aksözen, J., & Tran, C. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04367-6
Accelerating Drug Discovery and Development: Harnessing AI for Enhanced Efficiency and Speed
Sajithabanu, S., Ramachandran, M. S., Anand, A. J., & Samundeeswari, K. (2026) · Springer eBooks · doi:10.1007/978-3-032-23626-5_13
Yuan, J., Li, M., Jiang, B., Lu, Z. K., Zhao, J., & Jiang, X. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-108748
Blonda, A. M., Ollendorf, D. A., Huys, I., Denier, Y., & Simoens, S. (2026) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462326104127
Metadata
- Authors
- Tambuyzer, E.
- Corresponding author
- Tambuyzer, Erik
- Venue
- Nature Reviews Drug Discovery
- Published
- 2010-11-09
- Volume
- 9
- Issue
- 12
- Pages
- 921-929
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2019375534
- Cited by
- 182
- References
- 7
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 13 · 2021: 16 · 2020: 7 · 2019: 11 · 2018: 6 · 2017: 13 · 2016: 10 · 2015: 7 · 2014: 15 · 2013: 15 · 2012: 17
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- rare diseases, orphan drugs, orphan drug regulation, regulatory incentives, drug pricing, health care system impact, patient advocacy, pharmaceutical industry perspective
- MeSH terms
- Humans, Orphan Drug Production, United States, United States Food and Drug Administration, Drug Approval, Rare Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.